Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransIT: URD BMT vs IST for Severe Aplastic Anemia
NCT05600426Phase 3Terminated
- Sponsor
- Boston Children's Hospital
- Start
- Jan 2023
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of antilymphocyte immunoglobulin (horse), cyclosporine, antithymocyte globulin rabbit, fludarabine, cyclophosphamide in aplastic anemia, sponsored by Boston Children's Hospital. Started Jan 2023; status: terminated.
02
Drugs
antilymphocyte immunoglobulin (horse)cyclosporineantithymocyte globulin rabbitfludarabinecyclophosphamide
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT05600426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600426.